• BIVDA members area

Members' Press Releases

From the monthly archives: December, 2016

We are pleased to present below all posts archived in 'December, 2016'. If you still can't find what you are looking for, try using the search box.

OGT expands Cytocell sarcoma FISH probe range


Oxford, UK – 15 December 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of Cytocell Aquarius® fluorescence in situ hybridisation (FISH) probes for pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available, facilitating cancer research and diagnosis.

Read the rest of entry »

New data demonstrate that Oncotype DX® can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy

Genomic Health

LONDON, [December 12, 2016] – New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analysing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and guide treatment decisions without compromising outcomes.

Bear H.D. et al. Using the 21gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. San Antonio Breast Cancer Symposium. December 2016.

Read the rest of entry »

BBI Solutions launches a new enzyme for Urinalysis

BBI Solutions

BBI Solutions (BBI) today announced the launch of Porcine Liver Esterase (PLE), a new enzyme for Urinalysis, which is available to sample now.

Read the rest of entry »

OGT releases targeted NGS panel to study SNV and CNV in Familial Hypercholesterolemia

Oxford Gene Technology

Oxford, UK – 08 December 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its customisable SureSeq™ NGS panel range with the launch of the SureSeq myPanel™ NGS Custom FH Panel – allowing fast and cost-effective study of variants in familial hypercholesterolemia (FH). The new panel delivers both single nucleotide variation (SNV) and copy number variation (CNV) detection on a single small NGS panel assay and allows customisation by ‘mix and match’ of fully-tested and optimised gene and hotspot content. This includes all exons for LDLR, PCSK9, APOB, LDLRAP1, APOE, LIPA and STAP1 and a further 14 single-nucleotide polymorphisms (SNPs). This enables researchers to selectively sequence relevant regions, increasing throughput and saving on reagents.

Read the rest of entry »

QuantuMDx receives grant funding from Gates Foundation for diagnostic to reach the missing 4.3 million TB cases a year


28th November 2016, Newcastle upon Tyne, UK. QuantuMDx announced today that it received funding from the Bill & Melinda Gates Foundation to further develop and test its CAPTURE-XT™ pathogen concentration technology and Q-POC™ molecular diagnostic (MDx) platform for rapid low cost TB detection and drug susceptibility testing (DST) in response to World Health Organisation target product profiles. The technology is being developed for introduction into peripheral microscopy centres, clinics and hospitals in high burden countries, finally providing a low cost MDx solution to reach the 4.3 million people with TB who are ‘missed’ by healthcare systems each year.

Read the rest of entry »

Cytox presentations on studies with breakthrough genetic biomarker research assay for Alzheimer’s disease risk assessment at CTAD 2016


1st December 2016, Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced that it will be presenting two posters at the Clinical Trials on Alzheimer’s Disease Conference, CTAD 2016, San Diego, USA, December 8-10th, discussing SNP (single nucleotide polymorphism) profiling and the use of polygenic risk score algorithms for stratification of early subjects for risk of Alzheimer's disease (AD).

Read the rest of entry »